Share “BIND Therapeutics falls in 1st day on Nasdaq”

BIND Therapeutics falls in 1st day on Nasdaq

Published on NewsOK Modified: September 20, 2013 at 5:07 pm •  Published: September 20, 2013

NEW YORK (AP) — Shares of drug developer BIND Therapeutics fell in its first day of trading on the Nasdaq.

The stock dropped 91 cents, or 6.1 percent, to close at $14.09 Friday after raising $70.5 million in an initial public offering of stock.

BIND Therapeutics Inc. priced the offering of 4.7 million shares at $15 each, in the middle of the expected range.

BIND Therapeutics has no products on the market. Its most advanced treatment candidate, BIND-014, is in mid-stage clinical development as a possible treatment for a form of lung cancer and an advanced form of prostate cancer. The company plans to use the offering's proceeds in part to fund BIND-014 development.

The Cambridge, Mass., company trades under the "BIND" ticker symbol.


  1. 1
    Oregon pot stores sell more than $11 million in first 5 days
  2. 2
    Sigourney Weaver turns 66: Then and now
  3. 3
    Not Sucking in Their Seventies: Rock Lifers Go the Distance
  4. 4
    Explosions rock north Tulsa residential area
  5. 5
    Claremore hospital fires doctor who authorities say threatened officer after DUI arrest
+ show more


× Trending business Article